BioAge Labs, Inc.
Financial highlights
| Metric | FY December 31, 2025 | FY December 31, 2024 | FY December 31, 2023 |
|---|---|---|---|
| Revenue | $9.0M | $0 | — |
| Operating income | -$92.8M | -$78.2M | -$48.4M |
| Operating expenses | $101.8M | $78.2M | $48.4M |
| Cash from operations | -$81.6M | -$51.5M | -$37.4M |
| Capital expenditure | $719,000 | $366,000 | $166,000 |
| Free cash flow | -$82.3M | -$51.9M | -$37.5M |
| Total assets | $294.9M | $358.2M | $25.9M |
| Total liabilities | $22.8M | $35.1M | $66.6M |
| Total debt | $2.0M | $8.0M | — |
Shares outstanding 44.5M · Free float 83.8%
Annual filing data through FY ended December 31, 2025; float as of June 27, 2026.